The stock faces a binary outcome by July 29, 2026: either the bid price recovers above $1 for 20 consecutive days, or Nasdaq delists the stock. Delisting would severely reduce liquidity and institutional ownership. Monitor daily bid price and any capital-raising or reverse-split announcements. The recent insider buying suggests some confidence, but the prior reverse split failure is a strong negative signal.
Price Chart
Executive Summary
Nasdaq Hearings Panel granted HCW Biologics an extension until July 29, 2026 to regain compliance with the $1 minimum bid price rule, following a hearing on May 5, 2026. The company must demonstrate a bid price at or above $1 for 20 consecutive trading days by the deadline, or face immediate delisting. The company was not eligible for the standard 180-day cure period due to a prior reverse stock split.
Key Facts
- Nasdaq Hearings Panel granted an extension to July 29, 2026 to regain compliance with the $1 minimum bid price rule.
- Company must exhibit a bid price at or above $1 for 20 consecutive trading days by July 29, 2026.
- If the company becomes deficient with the Bid Price Rule before September 22, 2026, it will be immediately delisted.
- Company was not afforded the standard 180-day cure period because it had already effected a 1-for-40 reverse stock split on April 11, 2025.
- If compliance is regained, the Panel intends to impose a Discretionary Panel Monitor for an additional one-year period.
- Market cap is approximately $13 million, and recent insider buying totaled $430,000 over 30 days.
Financial Impact
No financial figures provided in the filing. The $13M market cap and $430K insider buying are from market data snapshot, not the filing.
Risk Factors
- Failure to meet the July 29, 2026 deadline would result in immediate delisting from Nasdaq.
- Any deficiency in the Bid Price Rule before September 22, 2026 triggers immediate delisting without further cure.
- Non-compliance with any other listing rule before September 22, 2026 could also lead to delisting.
- The company has already exhausted a reverse stock split to address the bid price issue, limiting available remedies.
- Delisting would likely cause a sharp decline in stock price and trading volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026529 |
| Document: 0001493152-26-026529-index-headers.html | 0001493152-26-026529 |
| Document: 0001493152-26-026529-index.html | 0001493152-26-026529 |
| Document: 0001493152-26-026529.txt | 0001493152-26-026529 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.10 (+12.70%) |
Oct 2, 2026 24d ago | S-1 | $1.64 | awaiting T+60 | — | $1.10 (+32.93%) |
Oct 1, 2026 25d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.10 (+34.91%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.10 (+44.72%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.10 (−48.11%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.10 (+58.96%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.10 (+57.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers